Veranex, the provider of the first purpose-built global service platform for the medtech industry, has officially announced the acquisition of T3 Labs, a highly esteemed preclinical laboratory situated in Atlanta, Georgia.
This strategic move solidifies Veranex's dedication to expanding its preclinical presence in North America, deepening its therapeutic expertise, and offering clients increased flexibility.
Pat Donnelly, Veranex's CEO, expressed the significance of adding T3 Labs to the Veranex family, stating that it aligns with their mission of unifying the entire medtech development process, from concept to commercialization.
Donnelly emphasized the growing preclinical market, escalating regulatory requirements, and the necessity for efficient collaboration between clients and their product development partners, making T3 Labs a strategic fit and an invaluable asset for Veranex's clients.
T3 Labs stands out as a leader in preclinical evaluation services in the United States, boasting a 33,000-square-foot facility equipped with innovative technology, training facilities, and state-of-the-art operating rooms dedicated to research in 12 therapeutic areas.
Situated in Science Square, an emerging life sciences hub in Atlanta, Georgia, T3 Labs shares strategic community relationships with notable institutions such as the Centers for Disease Control and Prevention (CDC), Emory University, and Georgia Tech.
The experienced staff at T3 Labs has played a key role in obtaining FDA clearance for over 60 products in the past decade. This acquisition complements Veranex PCS France, which has a 25-year history of delivering world-class preclinical services, thereby offering customers comprehensive and turn-key preclinical service offerings.
T3 Labs is led by Sherry Farrugia, an entrepreneur and executive leader with over 30 years of leadership experience in the healthcare and medical device industry, and Dr. Jeff White, a biomedical operations executive with extensive experience in medtech innovation operations.
Sherry Farrugia expressed enthusiasm about joining the Veranex family, highlighting the potential to better serve the greater medtech and Science Square community. The collaboration between T3 Labs and Veranex aims to leverage their combined expertise and offerings to make a significant impact for clients and the broader healthcare industry.
Dr. Jeff White added, "Veranex upholds very high standards for the services it provides to its clients, a value that the company and T3 Labs have in common. Together, T3 Labs and Veranex can deliver more integrated, valuable, customized services to the medtech community. We look forward to our future contributions."
Note: Content may be edited for style and length.
Source
